Invitrogen, BioReliance, Viropro, Beckman, Biosite, Stratagene, Agilent, Affymetrix, NuGen, Waters, EPA, Sigma-Aldrich, Thermo Fisher, VWR, Cepheid, Blue Stream, Cogenics, Keygene, Roche, Illumina | GenomeWeb
Invitrogen Closes Sale of BioReliance, Inks R&D Alliance with Viropro
Invitrogen has closed the $210 million sale of its BioReliance unit to Avista Capital Partners as part of its plans to better organize some of its acquisitions and streamline its focus, the company said last week.
Two months ago, Invitrogen agreed to sell the biological services unit to Avista in an effort to focus on its platform of scientific technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.